Io Biotech Stock Today
| IOBT Stock | USD 0.68 0.04 6.25% |
PerformanceWeakest
| Odds Of DistressSmall
|
IO Biotech is selling for under 0.68 as of the 4th of December 2025; that is 6.25 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.66. IO Biotech has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 5th of September 2025 and ending today, the 4th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 2021 | Category Healthcare | Classification Health Care |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 71.95 M outstanding shares of which 2.43 M shares are currently shorted by private and institutional investors with about 0.49 trading days to cover. More on IO Biotech
Moving against IOBT Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IOBT Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIO Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IO Biotech's financial leverage. It provides some insight into what part of IO Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
IO Biotech (IOBT) is traded on NASDAQ Exchange in USA and employs 80 people. IO Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.51 M. IO Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 71.95 M outstanding shares of which 2.43 M shares are currently shorted by private and institutional investors with about 0.49 trading days to cover.
IO Biotech currently holds about 170.12 M in cash with (82.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check IO Biotech Probability Of Bankruptcy
Ownership AllocationIO Biotech secures a total of 71.95 Million outstanding shares. 30% of IO Biotech outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check IOBT Ownership Details
IOBT Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sectoral Asset Management Inc | 2025-06-30 | 117.7 K | |
| Bridgeway Capital Management, Llc | 2025-06-30 | 75 K | |
| Geode Capital Management, Llc | 2025-06-30 | 33.3 K | |
| Xtx Topco Ltd | 2025-06-30 | 29.2 K | |
| Citadel Advisors Llc | 2025-06-30 | 28.9 K | |
| Jane Street Group Llc | 2025-06-30 | 25.9 K | |
| Goss Wealth Management Llc | 2025-06-30 | 24.2 K | |
| Ubs Group Ag | 2025-06-30 | 13.3 K | |
| Cubist Systematic Strategies, Llc | 2025-06-30 | 13.1 K | |
| Vivo Capital, Llc | 2025-06-30 | 6.2 M | |
| Novo A/s | 2025-06-30 | 3.4 M |
IO Biotech Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. IO Biotech market risk premium is the additional return an investor will receive from holding IO Biotech long position in a well-diversified portfolio.
| Mean Deviation | 7.82 | |||
| Semi Deviation | 13.82 | |||
| Standard Deviation | 13.39 | |||
| Variance | 179.33 |
IOBT Stock Against Markets
IO Biotech Corporate Management
| MaiBritt Zocca | President, Founder | Profile | |
| Qasim MD | Chief Officer | Profile | |
| Faical Miyara | Chief Officer | Profile | |
| Brian CPA | Chief Officer | Profile | |
| Amy Sullivan | Chief Officer | Profile | |
| Anders Ljungqvist | Founder | Profile | |
| Brian Burkavage | Chief Officer | Profile |
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.